News Archive - Page 2 of 7

Lifecare study confirm clinical accuracy in line with gold standard

June 20, 2023
Data from Lifecare’s Clinical Development Study LFC-SEN-001 confirm that the Company’s Continuous Glucose Monitoring (CGM) system (Sencell) has a solid clinical accuracy: the mean average of absolute error (MARD) between Sencell and matched relative reference values was 9,6%. In context, regulatory authorities expect a MARD below 10% to acknowledge CGM for therapeutic (medical) decisions […]
Read more

Lifecare launches spin-off company with successful veterinary

May 30, 2023
Lifecare is launching a new company called Lifecare Veterinary. Now man’s best friend will also benefit from the same innovation. – Our main focus will still be the development of the sensor for people with diabetes, increasing their quality of life. This is not, however, counterproductive to helping our pets in parallel to the […]
Read more

Information from Lifecare – May 2023

May 12, 2023
Finalized successful Sencell clincal study Today we can announce that we have finalized the Sencell Clinical Development Study (LFC-SEN-001) and it reveals accurate sensor performance in human subjects. – This is a very important step in the right direction to develop the next generation Continuous Glucose Monitor (CGM) for people with diabetes, says CEO Joacim Holter. […]
Read more

Information from Lifecare – April 2023

April 11, 2023
Update on Sensor longevity Today, Lifecare is pleased to announce that a sensor first used in our ongoing Clinical Development Study has confirmed an operational longevity of 12 weeks in a continued laboratory (in vitro) set up. This is yet another important milestone in the development of our Sencell technology for Continuous Glucose Monitoring […]
Read more

Information from Lifecare – March 2023 #2

March 31, 2023
Update on Clinical Development Study The Clinical Development Study with the Sencell sensor will continue for a few more weeks. – We operate complex and pioneering sensor technology and strive to ensure high quality at all stages of the process. We therefore want to extend the Clinical Development Study by a few weeks […]
Read more

Annual Report 2022 – Important milestone achievements

March 28, 2023
For Lifecare 2022 was characterized by confirmation of the technology, Clinical Development Study, and building an organization that makes us even more robust and competent to face upcoming challenges. – Important milestone achievements naturally provide a good basis for the ongoing work related to the glucose sensor, CEO Joacim Holter states. Lifecare’s Annual Report 2022 […]
Read more

Information from Lifecare – March 2023

March 23, 2023
Successful ISO audit at Lifecare Laboratory in Germany Lifecare is pleased to announce that its wholly owned subsidiary Lifecare Laboratory GmbH in Mainz, Germany, has been successfully audited as part of the upcoming ISO certification. “It is reassuring that our operational organization has passed this audit without any major findings. This is a good […]
Read more

Information from Lifecare – February 2023 #3

February 28, 2023
Q4 2022 Report Lifecare AS will present Q4 2022 Report on Tuesday 28 February. The webcast will be for all shareholders and interested parties at 12:30 – 13:15 CET. Lifecare CEO Joacim Holter will participate in the webcast. There will be a Q&A session following the presentation. The webcast will be available here: Link to Teams meeting […]
Read more

Information from Lifecare – February 2023 #2

February 22, 2023
Important week for Lifecare in Berlin at the 16th international conference on Advanced Technologies & Treatments for Diabetes (ATTD) The upcoming days Lifecare will be productive and important for Lifecare in in Berlin where two presentations will be held at the prestigious conference ATTD. The company will also attend the steering committee of the […]
Read more

Information from Lifecare – February 2023

February 6, 2023
Sensor longevity breakthrough in Lifecare Ongoing clinical development study confirms Lifecare’s expectation of a sensor longevity that far exceeds the lifetime of existing and commercially available needle sensors for glucose monitoring. CSO Prof. Andreas Pfützner and CEO Joacim Holter Today Lifecare can report that sensors used in a three-day clinical study continue to […]
Read more